The impact of new weight loss treatments is being felt well beyond the health-care industry . Analysts used the ritual of quarterly earnings calls to probe companies on whether their businesses were being helped — or hampered by — the latest trend. Drugs that mimic gut hormones like glucagon-like peptide-1, or GLP-1, were first used to treat diabetes, but have gained favor as obesity treatments.
Cardinal Health also said the medications provided a tailwind to its revenue for another quarter. The company raised its fiscal 2024 pharmaceutical sales outlook, citing help from the drugs. Employers watch health-care costs More than 40% of the U.S. adult population is considered obese, and some worry health-care costs will rise rapidly as the drugs become widely used. Some companies already bar weight loss medications from their insurance plans to keep costs down.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
La source: nbcchicago - 🏆 545. / 51 Lire la suite »
La source: CNBC - 🏆 12. / 72 Lire la suite »
La source: CNBC - 🏆 12. / 72 Lire la suite »